An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening

Fatima Amanat, Kris M. White, Lisa Miorin, Shirin Strohmeier, Meagan McMahon, Philip Meade, Wen Chun Liu, Randy A. Albrecht, Viviana Simon, Luis Martinez-Sobrido, Thomas Moran, Adolfo García-Sastre, Florian Krammer

Research output: Contribution to journalArticlepeer-review

111 Scopus citations


The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS-CoV-2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS-CoV-2 in vitro.

Original languageEnglish
Article numbere108
JournalCurrent Protocols in Microbiology
Issue number1
StatePublished - 1 Sep 2020


  • COVID-19
  • COVID19
  • SARS-CoV-2
  • antivirals
  • medium-throughput screening
  • microneutralization
  • neutralization


Dive into the research topics of 'An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening'. Together they form a unique fingerprint.

Cite this